聚腺苷二磷酸核糖聚合酶抑制剂在卵巢癌治疗中的应用：综述。
PARP inhibitors in the treatment of ovarian cancer: a review.
机构信息
Division of Obstetrics and Gynecology, Department of Gynecologic Oncology, University of Oklahoma Health Science Center, Stephenson Cancer Center, Oklahoma City, Oklahoma, USA.
出版信息
Curr Opin Obstet Gynecol. 2021 Feb 1;33(1):1-6. doi: 10.1097/GCO.0000000000000675.
PURPOSE OF REVIEW
This article will review recent changes in the standard of care for olaparib, niraparib, and rucaparib, as well as ongoing trials evaluating this class of drugs in combination with antiangiogenic agents and PD-1/PD-L1 inhibitors.
RECENT FINDINGS
Niraparib received FDA approval for use in patients with complete response or partial response to first-line platinum-based chemotherapy regardless of BRCAm or HRD status that was received in April 2020. FDA approval was received for olaparib in combination with bevacizamab for epithelial ovarian cancer patients with complete response/partial response to first-line chemotherapy and bevacizumab and g/sBRCA and/or genomic instability by Myriad myChoice CDx in May 2020.
SUMMARY
In the last year, treatment with PARPi has extended to not only include BRCAm and HRD-deficient patients but also have shown improvement in outcomes in HRD-proficient patients. With these advancements, more patients can access these agents and receive benefit. In the upcoming years, it will be exciting to see the potential benefit when PARPs are added to other angiogenic antagonists and immunotherapy agents.
目的综述
本文将综述奥拉帕利、尼拉帕利和鲁卡帕利的治疗标准的最新变化，以及正在进行的临床试验，评估这类药物与抗血管生成药物和 PD-1/PD-L1 抑制剂联合应用的效果。
最近的发现
尼拉帕利于 2020 年 4 月获得 FDA 批准，用于一线铂类化疗完全缓解或部分缓解的患者，无论 BRCA 突变状态或 HRD 状态如何。2020 年 5 月，奥拉帕利联合贝伐珠单抗获得 FDA 批准，用于一线化疗完全缓解/部分缓解、贝伐珠单抗和 g/sBRCA 以及/或 Myriad myChoice CDx 检测到基因组不稳定性的上皮性卵巢癌患者。
总结
在过去的一年中，PARPi 的治疗不仅扩展到包括 BRCA 突变和 HRD 缺陷型患者，而且在 HRD 阳性患者中也显示出了更好的疗效。随着这些进展，更多的患者可以获得这些药物并从中获益。在未来几年，当 PARP 抑制剂与其他血管生成拮抗剂和免疫治疗药物联合应用时，其潜在的获益将令人兴奋。
Zotero 插件